US Patent

US9790208 — Crystalline salt form of (S)-(2-(6-chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist

Composition of Matter · Assigned to Idorsia Pharmaceuticals Ltd · Expires 2034-12-02 · 9y remaining

Vulnerability score 0/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects a crystalline form of the drug substance DARIDOREXANT HYDROCHLORIDE, an orexin receptor antagonist.

USPTO Abstract

The invention relates to a crystalline form of (S)-(2-(6-chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone hydrochloride, processes for the preparation thereof, pharmaceutical compositions containing said crystalline form, and its use as medicament, especially as orexin receptor antagonist.

Drugs covered by this patent

daridorexant-hydrochloride (DARIDOREXANT HYDROCHLORIDE)

Patent Metadata

Patent number: US9790208
Jurisdiction: US
Classification: Composition of Matter
Expires: 2034-12-02
Drug substance claim: Yes
Drug product claim: Yes
Assignee: Idorsia Pharmaceuticals Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.